Citadel Advisors LLC Makes New $4.15 Million Investment in Seaport Therapeutics, Inc. $SPTX

Citadel Advisors LLC purchased a new stake in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) during the 2nd quarter, HoldingsChannel reports. The firm purchased 191,144 shares of the company’s stock, valued at approximately $4,152,000.

Several other institutional investors have also recently modified their holdings of SPTX. TRV GP VI LLC purchased a new position in Seaport Therapeutics during the 2nd quarter worth approximately $44,769,742. Braidwell LP purchased a new stake in shares of Seaport Therapeutics in the 2nd quarter valued at $10,860,000. Alyeska Investment Group L.P. purchased a new stake in shares of Seaport Therapeutics in the 2nd quarter valued at $1,629,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Seaport Therapeutics in the second quarter worth $362,000.

Analyst Ratings Changes

SPTX has been the subject of several recent research reports. Leerink Partners started coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $35.00 target price for the company. JPMorgan Chase & Co. began coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They set an “overweight” rating and a $42.00 price target on the stock. BNP Paribas Exane lowered Seaport Therapeutics to a “market perform” rating in a research note on Tuesday, May 26th. Seaport Research Partners set a $32.00 price objective on Seaport Therapeutics in a report on Tuesday, August 25th. Finally, Zacks Research upgraded Seaport Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Seaport Therapeutics has a consensus rating of “Hold” and an average price target of $37.33.

Insider Buying and Selling at Seaport Therapeutics

In other Seaport Therapeutics news, Director Robert Hombach purchased 13,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the purchase, the director directly owned 13,000 shares in the company, valued at approximately $235,820. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Seaport Therapeutics Stock Performance

SPTX stock opened at $24.86 on Tuesday. The firm has a market capitalization of $1.33 billion and a price-to-earnings ratio of -2.05. The firm’s fifty day moving average price is $22.34. Seaport Therapeutics, Inc. has a one year low of $14.85 and a one year high of $28.38.

Seaport Therapeutics (NASDAQ:SPTX) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). Research analysts predict that Seaport Therapeutics, Inc. will post -4.6 EPS for the current year.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.